C5抑制剂Avacincaptad Pegol治疗年龄相关性黄斑变性所致地图样萎缩:随机关键性2/3期试验
GATHER1研究为国际、前瞻性、随机、双盲、假注射对照的关键性2/3期临床试验,纳入286例年龄相关性黄斑变性继发地图样萎缩的受试者。结果显示,Avacincaptad Pegol 2 mg和4 mg组12个月内地图样萎缩生长平均速率分别降低27.4%(P=0.0072)和27.8%(P=0.0051),均具统计学显著性,且总体耐受性良好。
要点
- Avacincaptad Pegol 2 mg和4 mg每月玻璃体腔注射可使地图样萎缩12个月生长速率分别降低27.4%和27.8%。
- 两个剂量组结果均具统计学显著性,总体耐受性良好,无药物相关不良事件或炎症。
- 未观察到眼部严重不良事件或眼内炎,最常见眼部不良事件与注射操作相关。
核心结论
- 玻璃体腔注射Avacincaptad Pegol 2 mg和4 mg可在12个月内显著降低年龄相关性黄斑变性患眼的地图样萎缩生长。
研究设计与样本
- 国际、前瞻性、随机、双盲、假注射对照的关键性2/3期临床试验(GATHER1研究)。
- 共纳入286例年龄相关性黄斑变性继发地图样萎缩的受试者。
主要发现
- 12个月内地图样萎缩生长平均速率(平方根转换)在Avacincaptad Pegol 2 mg组降低27.4%(P=0.0072)。
- 12个月内地图样萎缩生长平均速率(平方根转换)在Avacincaptad Pegol 4 mg组降低27.8%(P=0.0051)。
- 两个剂量组结果均具统计学显著性,Avacincaptad Pegol每月给药12个月总体耐受性良好。
- 无Avacincaptad Pegol相关不良事件或炎症,无眼部严重不良事件,无眼内炎病例。
- 最常见眼部不良事件与注射操作相关。
关键数值与推荐
- 主要疗效终点为12个月内通过眼底自发荧光(FAF)在基线、第6个月和第12个月三个时间点测量的地图样萎缩平均变化速率。
- Avacincaptad Pegol 2 mg组12个月地图样萎缩生长平均速率降低27.4%(P=0.0072),4 mg组降低27.8%(P=0.0051),均与相应假注射组比较。
临床怎么用
- Avacincaptad Pegol每月玻璃体腔注射可显著减缓年龄相关性黄斑变性继发地图样萎缩的生长,且总体耐受性良好。
- C5抑制理论上保留C3活性,可能提供额外安全性优势。
- 第二项确证性关键临床试验(GATHER2研究)正在进行,以确认Avacincaptad Pegol减缓地图样萎缩生长的疗效和安全性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The complement pathway may play a key role in the pathogenesis of age-related macular degeneration (AMD). The safety and efficacy of avacincaptad pegol (Zimura, IVERIC bio Inc, New York, NY), a C5 inhibitor, were assessed in participants with geographic atrophy (GA) secondary to AMD (GATHER1 Study). DESIGN: International, prospective, randomized, double-masked, sham-controlled, pivotal phase 2/3 clinical trial. PARTICIPANTS: A total of 286 participants with GA secondary to AMD. MAIN OUTCOME MEASURES: The primary efficacy endpoint was the mean rate of change in GA over 12 months measured by fundus autofluorescence (FAF) at 3 timepoints: baseline, month 6, and month 12. RESULTS: The reduction in the mean rate of GA growth (square root transformation) over 12 months was 27.4% (P = 0.0072) for the avacincaptad pegol 2 mg cohort and 27.8% (P = 0.0051) for the avacincaptad pegol 4 mg cohort compared with their corresponding sham cohorts. The results for both dose groups were statistically significant. Avacincaptad pegol was generally well tolerated after monthly administration over 12 months. There were no avacincaptad pegol-related adverse events (AEs) or inflammation. Further, there were no ocular serious AEs (SAEs) and no cases of endophthalmitis. The most frequent ocular AEs were related to the injection procedure. CONCLUSIONS: Intravitreal administration of avacincaptad pegol 2 mg and 4 mg led to a significant reduction of GA growth in eyes with AMD over a 12-month period. Because C5 inhibition theoretically preserves C3 activity, it may offer additional safety advantages. A second confirmatory pivotal clinical trial is underway to confirm the efficacy and safety of avacincaptad pegol in slowing the GA growth (GATHER2 Study).
引用
- Jaffe GJ, Westby K, Csaky KG, et al. C5 Inhibitor Avacincaptad Pegol for Geographic Atrophy Due to Age-Related Macular Degeneration: A Randomized Pivotal Phase 2/3 Trial. Ophthalmology. 2020. PMID: 32882310. doi:10.1016/j.ophtha.2020.08.027
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。